Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P10s-PADRE vaccine in advanced lung cancer
NCT02264236Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Oct 2015
- Primary completion
- Jun 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of P10s-PADRE in lung cancer, sponsored by University of Arkansas. Primary endpoints: Number of participants with vaccine related adverse events at 64 weeks and Number of participants with vaccine induced immune related response at 64 weeks. Planned start Oct 2015; status: withdrawn.
02
Drugs
P10s-PADRE
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02264236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264236.